Starting a GLP-1 medicine can sound deceptively simple online: ask for the drug, start the dose, wait for appetite to change. A safer clinician conversation is wider than that. It should cover why the medicine is being considered, whether the label and evidence fit the situation, which warnings matter for the patient’s history, how side effects will be handled, and what the long-term plan looks like if weight, coverage, pregnancy plans, or tolerability change.
Use this as a visit-prep checklist, not a self-treatment protocol. The goal is to ask better questions so a licensed clinician can make a safer, more specific recommendation.
1. Which medicine, indication, and evidence are we actually discussing?
Ask whether the conversation is about an FDA-approved semaglutide or tirzepatide product, another approved GLP-1 or incretin medicine, a compounded version, or an investigational product. These categories are not interchangeable. Evidence from a branded, FDA-approved product does not automatically validate a compounded, research-use, or gray-market product.
A practical question: ‘Which labeled indication and which evidence base are we using for my situation?’ The answer should separate type 2 diabetes, chronic weight management, cardiovascular-risk discussions, off-label use, and pipeline speculation.
2. What in my medical history changes the risk conversation?
Product labels and patient information emphasize that GLP-1 and related incretin medicines are not a casual wellness purchase. Ask specifically about personal or family history that could change the risk-benefit discussion, including pancreatitis history, gallbladder disease, severe gastrointestinal disease, kidney issues related to dehydration, diabetes medications that can cause low blood sugar, pregnancy or plans to become pregnant, breastfeeding, and eating-disorder history.
This is also where the clinician should review current medicines and supplements. The right question is not ‘Is this drug safe?’ in the abstract. It is ‘What would make this medicine a bad fit for me?’
3. What side effects should trigger a call, pause, or urgent care?
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, and appetite changes are commonly discussed. Serious warnings deserve equal clarity. Ask what symptoms could suggest pancreatitis, gallbladder problems, dehydration, kidney stress, allergic reaction, severe persistent abdominal pain, or other issues that should not be managed through social-media advice.
Before leaving the visit, ask for a written plan: who to contact, what symptoms are urgent, how to handle missed doses, and when a side effect means the dose should not be increased.
4. How will we protect nutrition, strength, and lean mass?
Appetite reduction can be useful, but eating less is not a complete plan. Ask how protein, hydration, fiber, micronutrients, constipation prevention, resistance training, and unintended rapid weight loss will be monitored. If nausea limits intake, the plan should not be simply ‘push through it.’
The best visit turns the medicine into one part of a larger care plan: nutrition quality, strength training, sleep, alcohol use, mental health, and follow-up labs or measurements when appropriate.
5. What is the monitoring and follow-up schedule?
Ask what the clinician wants to track at baseline and follow-up: weight trend, waist or body-composition context where available, blood pressure, glucose or A1C when relevant, lipids, kidney function, gastrointestinal symptoms, medication interactions, and quality-of-life changes. Monitoring should match the reason the medicine is being used.
Also ask when the plan will be reassessed. A useful target is not only ‘Did the scale move?’ It is ‘Are benefits, side effects, cost, and adherence still making sense together?’
6. What happens if coverage changes, I plateau, or I want to stop?
Many GLP-1 conversations focus on starting. Long-term decisions can be harder: prior authorization, shortages, cost, plateau management, dose changes, side effects, surgery, pregnancy planning, or a desire to discontinue. Ask about these before they become emergencies.
A good question is: ‘If this works, what is our maintenance plan? If I stop or cannot access it, what is our plan for appetite, nutrition, weight regain risk, and follow-up?’
7. How should I think about compounded GLP-1 products?
The FDA has warned about concerns involving unapproved GLP-1 drugs used for weight loss, including issues around compounded semaglutide and tirzepatide products, dosing errors, and products that are not FDA-approved versions. Readers should not assume that a compounded product has the same evidence, oversight, or quality controls as an FDA-approved branded medicine.
If a clinician discusses a compounded option, ask what exact ingredient and salt form is being used, why it is being considered, how the pharmacy is vetted, how dosing will be measured, and what monitoring and adverse-event reporting plan is in place. This is a clinician-level risk conversation, not a supplier-shopping exercise.
Questions to bring to the appointment
What diagnosis or health goal makes me a candidate? Which product and label are we discussing? What would make this unsafe for me? Which side effects are expected and which are urgent? How will we handle nausea, constipation, dehydration, or dose intolerance? What nutrition and strength plan should start now? What labs or follow-up do you want? What should I do if I miss a dose, travel, have surgery, become pregnant, lose coverage, or want to stop? If a compounded product is mentioned, how are quality, dosing, and reporting handled?
Bottom line
The Glow Diary’s view is simple: the most useful GLP-1 content does not hand readers a protocol. It helps them walk into a clinical conversation with better questions, clearer source boundaries, and less internet noise.
If the answer to a key question is vague — especially around product identity, side-effect escalation, pregnancy planning, compounded products, or long-term maintenance — that is not a reason to improvise. It is a reason to keep the conversation with a licensed clinician open.
Medical note
This review is for education only and is not medical advice. Treatment decisions should be made with a licensed clinician who knows your history, medications, labs, and goals.